Latest Regulatory Progress News

Paladin Energy completes Langer Heinrich Mine ramp-up, delivering strong FY2026 results and advancing its Canadian PLS Project with a new uranium discovery. FY2027 guidance forecasts stable production and costs amid ongoing regulatory progress.

Optiscan Imaging has kicked off a US clinical trial with Mayo Clinic to test its InVue and InForm devices in breast conserving surgery, aiming to generate data for FDA 510(k) submissions and validate a new surgical-pathology workflow.

AFT Pharmaceuticals has received tentative US FDA approval for its Scomara cream to treat Facial Angiofibromas in Tuberous Sclerosis, but US commercialisation is postponed until 2029 due to orphan drug exclusivity. The approval bolsters regulatory prospects in other key markets where AFT anticipates competitive advantages.

Yancoal's June quarter saw a 20% jump in attributable saleable coal production to 10.8 million tonnes, supported by rising realised coal prices and operational improvements. The company advances its strategic growth with the pending acquisition of an 80% stake in the Kestrel Coal Mine, while planning to close Ashton mine by early 2028.

VHM Limited has secured a binding rare earths offtake and a A$40 million convertible note from Iluka Resources, underpinning the Goschen Project's path to production by late 2027.

Resolution Minerals has earned FAST-41 transparency status for its Golden Gate Project in Idaho, marking its second such designation and positioning the company as a key player in U.S. critical minerals supply chain development.

Netwealth Group posts a record $135.7 billion in funds under administration for FY26, driven by strong net flows and platform enhancements despite short-term geopolitical jitters.

Condor Energy has completed a pivotal feasibility study for its Piedra Redonda gas discovery offshore Peru, confirming a conventional development approach and underpinning ongoing commercial and financing efforts.

Neurotech International has locked in a $3.15 million secured loan against its anticipated R&D tax incentives to fund pivotal Phase III autism trials and ongoing operations.

Ora Banda Mining (ASX:OBM) reported a substantial expansion of its Mineral Resources and Ore Reserves at the Davyhurst Gold Project, driven by exploration success and significant drilling investment.

Resolution Minerals has completed 16 diamond core holes totalling 4,470 metres at its Golden Gate South prospect in Idaho, progressing one third of its 2026 drill program aimed at defining gold and tungsten mineralisation.

OncoSil Medical has completed key manufacturing validation cycles with Cyclotek, paving the way for scalable Australian production of its OncoSil™ device. With a $2.1 million capital investment, the company aims to boost margins and supply chain control ahead of commercial launch in late 2026.